Table of Contents
Centile Bioscience welcomed Hannah Mamuszka to its Advisory Board earlier this year. With a background in molecular and neurobiology, Hannah spent the past two decades building the diagnostics industry's commercial and economic infrastructure, work that took her from the National Institutes of Health through drug development at Millennium Pharmaceuticals to founding Alva10, where she helps diagnostic developers and payers align on value.
She previously held leadership roles as Vice President of Business Development and Clinical Strategy at Exosome Diagnostics, later acquired by Bio-Techne, and as Global Director of Pharmaceutical Services at Oncotech/Exiqon, later acquired by QIAGEN. She also serves on the board of directors of Bionano Genomics, a publicly traded genomics company, and as an Advisor to the Carolina Health Informatics Program (CHIP) at the University of North Carolina at Chapel Hill. She holds a Master of Science in Biological Sciences from Harvard University.
At Centile Bio, Hannah provides guidance on health economics, market access, and reimbursement strategy. As the company brings population-referenced measurement into clinical and pharmaceutical research and development programs, questions about reimbursement, value, and commercial pathways become central. Drawing on her expertise in diagnostics and health economics, Hannah helps Centile Bio address these challenges with a strong evidence-based approach.
Hannah has spent her career bridging translational science and the health systems, researchers, and drug developers who bring it into practice. That's exactly the experience Centile Bio needs to bring CentileOS into the everyday workflows of clinical diagnostics and drug development, a reference clinicians and researchers can finally build on with confidence.
— Jakob Seidlitz, PhD, Co-founder and CEO, Centile Bioscience
Centile Bio is building the quantitative imaging infrastructure precision neurology has been missing. I am eager to help guide its path forward by advising on adoption and market access strategy.
— Hannah Mamuszka, Strategic Advisor, Centile Bioscience
